Core Insights - Elicio Therapeutics is presenting new immunogenicity data from its Phase 2 AMPLIFY-7P trial of ELI-002 for mKRAS-driven pancreatic cancer at the SITC Annual Meeting [1] - The company aims to develop off-the-shelf immunotherapies targeting prevalent cancers, leveraging its proprietary AMP technology to enhance T cell responses [3][4] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [3] - The company's lead product candidate, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors [4][5] - Elicio's AMP technology is designed to improve the education and activation of cancer-specific T cells, promoting durable cancer immunosurveillance [3][7] Clinical Trials and Data - ELI-002 is currently being studied in a randomized clinical trial for patients with mKRAS-positive pancreatic cancer who are at high risk of relapse after standard therapy [3][5] - The AMPLIFY-201 Phase 1 trial data showed a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months for the full study population [3] - Elicio plans to expand ELI-002 to other indications, including mKRAS-positive lung cancer [3] Presentation Details - The late-breaking abstract presentation titled "AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P" will be presented by Dr. Lisa McNeil on November 7, 2025 [2] - Another poster presentation titled "AMP-Immunomodulator therapy controls growth and eradicates syngeneic solid tumors" will be presented by Dr. Martin Steinbuck on November 8, 2025 [3]
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting